Literature DB >> 26403323

A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma.

Allison Rosenthal1, Shaji Kumar2, Craig Hofmeister3, Jacob Laubach4, Ravi Vij5, Amylou Dueck1, Katherine Gano1, A Keith Stewart6.   

Abstract

Entities:  

Keywords:  alisertib; aurora kinase; bortezomib; multiple myeloma; relapse

Mesh：

Substances：

Year:  2015        PMID： 26403323      PMCID： PMC4820359          DOI： 10.1111/bjh.13765

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

1.  Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.

Authors:  Rodger E Tiedemann; Yuan Xao Zhu; Jessica Schmidt; Chang Xin Shi; Chris Sereduk; Hongwei Yin; Spyro Mousses; A Keith Stewart
Journal:  Cancer Res       Date:  2011-12-06       Impact factor: 12.701

2.  RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.

Authors:  Yuan Xiao Zhu; Rodger Tiedemann; Chang-Xin Shi; Holly Yin; Jessica E Schmidt; Laura A Bruins; Jonathan J Keats; Esteban Braggio; Chris Sereduk; Spyro Mousses; A Keith Stewart
Journal:  Blood       Date:  2011-02-02       Impact factor: 22.113

Review 3.  Aurora kinases: new targets for cancer therapy.

Authors:  Richard D Carvajal; Archie Tse; Gary K Schwartz
Journal:  Clin Cancer Res       Date:  2006-12-01       Impact factor: 12.531

4.  International uniform response criteria for multiple myeloma.

Authors:  B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar
Journal:  Leukemia       Date:  2006-07-20       Impact factor: 11.528

5.  Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations.

Authors:  E Claire Dees; Roger B Cohen; Margaret von Mehren; Thomas E Stinchcombe; Hua Liu; Karthik Venkatakrishnan; Mark Manfredi; Howard Fingert; Howard A Burris; Jeffrey R Infante
Journal:  Clin Cancer Res       Date:  2012-07-05       Impact factor: 12.531

6.  Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.

Authors:  Andres Cervantes; Elena Elez; Desamparados Roda; Jeffrey Ecsedy; Teresa Macarulla; Karthik Venkatakrishnan; Susana Roselló; Jordi Andreu; Jungah Jung; Juan Manuel Sanchis-Garcia; Adelaida Piera; Inma Blasco; Laura Maños; José-Alejandro Pérez-Fidalgo; Howard Fingert; Jose Baselga; Josep Tabernero
Journal:  Clin Cancer Res       Date:  2012-07-02       Impact factor: 12.531

7.  Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.

Authors:  Gerald Falchook; Razelle Kurzrock; Launce Gouw; David Hong; Kimberly A McGregor; Xiaofei Zhou; Hongliang Shi; Howard Fingert; Sunil Sharma
Journal:  Invest New Drugs       Date:  2014-06-01       Impact factor: 3.850

8.  Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Authors:  Kevin R Kelly; Thomas C Shea; André Goy; Jesus G Berdeja; Craig B Reeder; Kevin T McDonagh; Xiaofei Zhou; Hadi Danaee; Hua Liu; Jeffrey A Ecsedy; Huifeng Niu; Ely Benaim; Swaminathan Padmanabhan Iyer
Journal:  Invest New Drugs       Date:  2013-12-20       Impact factor: 3.850
  8 in total
  11 in total

1.  CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma.

Authors:  Chang-Xin Shi; K Martin Kortüm; Yuan Xiao Zhu; Laura A Bruins; Patrick Jedlowski; Patrick G Votruba; Moulun Luo; Robert A Stewart; Jonathan Ahmann; Esteban Braggio; A Keith Stewart
Journal:  Mol Cancer Ther       Date:  2017-09-27       Impact factor: 6.261

Review 2.  The role of aurora A and polo-like kinases in high-risk lymphomas.

Authors:  Carlos Murga-Zamalloa; Kedar V Inamdar; Ryan A Wilcox
Journal:  Blood Adv       Date:  2019-06-11

3.  A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia.

Authors:  Hagop M Kantarjian; Michael W Schuster; Nitin Jain; Anjali Advani; Elias Jabbour; Erick Gamelin; Erik Rasmussen; Gloria Juan; Abraham Anderson; Vincent F Chow; Gregory Friberg; Florian D Vogl; Mikkael A Sekeres
Journal:  Am J Hematol       Date:  2017-06-05       Impact factor: 10.047

Review 4.  Cell cycle proteins as promising targets in cancer therapy.

Authors:  Tobias Otto; Piotr Sicinski
Journal:  Nat Rev Cancer       Date:  2017-01-27       Impact factor: 60.716

Review 5.  The Relevance of Aurora Kinase Inhibition in Hematological Malignancies.

Authors:  Caio Bezerra Machado; Emerson Lucena DA Silva; Beatriz Maria Dias Nogueira; Jean Breno Silveira DA Silva; Manoel Odorico DE Moraes Filho; Raquel Carvalho Montenegro; Maria Elisabete Amaral DE Moraes; Caroline Aquino Moreira-Nunes
Journal:  Cancer Diagn Progn       Date:  2021-07-03

Review 6.  The therapeutic potential of cell cycle targeting in multiple myeloma.

Authors:  Anke Maes; Eline Menu; Kim De Veirman; Ken Maes; Karin Vand Erkerken; Elke De Bruyne
Journal:  Oncotarget       Date:  2017-06-28

7.  Functional interplay between NF-κB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma.

Authors:  Laura Mazzera; Manuela Abeltino; Guerino Lombardi; Anna Maria Cantoni; Roberto Ria; Micaela Ricca; Ilaria Saltarella; Valeria Naponelli; Federica Maria Angela Rizzi; Roberto Perris; Attilio Corradi; Angelo Vacca; Antonio Bonati; Paolo Lunghi
Journal:  Haematologica       Date:  2019-04-04       Impact factor: 9.941

8.  Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity.

Authors:  Chang-Xin Shi; Yuan Xiao Zhu; Laura A Bruins; Cecilia Bonolo de Campos; William Stewart; Esteban Braggio; A Keith Stewart
Journal:  Mol Cancer Res       Date:  2020-06-19       Impact factor: 5.852

9.  The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.

Authors:  Susana Hernández-García; Laura San-Segundo; Lorena González-Méndez; Luis A Corchete; Irena Misiewicz-Krzeminska; Montserrat Martín-Sánchez; Ana-Alicia López-Iglesias; Esperanza Macarena Algarín; Pedro Mogollón; Andrea Díaz-Tejedor; Teresa Paíno; Brian Tunquist; María-Victoria Mateos; Norma C Gutiérrez; Elena Díaz-Rodriguez; Mercedes Garayoa; Enrique M Ocio
Journal:  Haematologica       Date:  2017-08-31       Impact factor: 9.941

Review 10.  Kinase inhibitors as potential agents in the treatment of multiple myeloma.

Authors:  Hanley N Abramson
Journal:  Oncotarget       Date:  2016-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.